Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,391 INR | -1.11% | +0.50% | +14.74% |
May. 03 | INDIA STOCKS-India's Nifty 50 slips from record high as IT stocks weigh | RE |
May. 02 | Ajanta Pharma's Consolidated Profit Nearly Doubles in Fiscal Q4 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With an expected P/E ratio at 38.09 and 32.38 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.74% | 3.63B | C+ | ||
+17.42% | 42.25B | B- | ||
+15.37% | 21.27B | B+ | ||
+19.33% | 15.23B | - | ||
+19.07% | 14.36B | B+ | ||
+50.86% | 12.74B | B | ||
-0.05% | 6.79B | - | - | |
-12.40% | 6.61B | B+ | ||
-8.87% | 5.73B | - | - | |
+14.28% | 5.66B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AJANTPHARM Stock
- Ratings Ajanta Pharma Limited